Stinging from a proxy loss and hungry for cash, GlaxoSmithKline bails on equity stake in Innoviva for a tidy $392M

Max Gelman

Senior Editor

Following a failed attempt to challenge a slate of new board candidates at a company in which it’s a significant minority shareholder, GlaxoSmithKline has sold …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Stinging from a proxy loss and hungry for cash, GlaxoSmithKline bails on equity stake in Innoviva for a tidy $392M

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Sting­ing from a proxy loss and hun­gry for cash, Glax­o­SmithK­line bails on eq­ui­ty stake in In­no­vi­va for a tidy $392M

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Stinging from a proxy loss and hungry for cash, GlaxoSmithKline bails on equity stake in Innoviva for a tidy $392M